|Bid||37.65 x 900|
|Ask||37.68 x 800|
|Day's Range||37.30 - 38.45|
|52 Week Range||22.22 - 53.90|
|Beta (3Y Monthly)||3.11|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 5, 2019 - Nov 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||62.13|
- CRISPR Therapeutics to receive non-exclusive access to certain KSQ IP for its allogeneic CAR-T programs - - KSQ Therapeutics to receive non-exclusive access to certain CRISPR.
Vertex (VRTX) inks collaboration agreement with privately-held biotech, Ribometrix, for developing up to three RNA-targeted treatments for serious diseases.
ZUG, Switzerland and CAMBRIDGE, Mass., Oct. 01, 2019 -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines.
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
The data demonstrate that the CyT49 pluripotent stem cell line, which has been shown to be amenable to efficient scaling and differentiation, can be successfully edited with CRISPR. The CyT49 pluripotent stem cell line is currently being used to generate islet progenitors for clinical trials.
CRISPR is a gene-editing technique that enables the targeting and editing of specific sequences in the human DNA. It has been around for a couple of years, and recently, researchers in the U.S. have started using it to alter the genes of adults suffering from progressive disorders and diseases. The scientific community largely shunned the experiment, as CRISPR is known to result in unwanted gene edits, which, in the case of embryos (as well as sperm and eggs), are carried over to their offspring.
In the absence of an approved product in Editas' (EDIT) portfolio, pipeline development remains in focus on the second-quarter earnings call.
Vertex (VRTX) beats on earnings and sales in second-quarter 2019. The company lifts its full-year revenue guidance, led by a solid CF products' performance, especially Symdeko.
The CRISPR pioneer is taking a slow-and-steady approach to drug development. If peers are overlooking one key element of gene editing, that approach could pay off.
CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of -24.69% and -97.31%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
-Provides update in ongoing Phase 1/2 clinical trials of CTX001® for patients with severe hemoglobinopathies- -Enrolling in Phase 1/2 clinical trial of CTX110™, targeting.
On Axovant's (AXGT) first-quarter fiscal 2019 earnings call, investor focus will be on its progress with the investigational pipeline candidates designed to treat debilitating neurological diseases.
On Vertex's (VRTX) second-quarter earnings call, investor focus will be on the adoption of its newest CF drug Symdeko and the update on its NDA filing for the VX-445 triple combination regimen.
On CNBC's "Mad Money Lightning Round," Jim Cramer said eBay Inc (NASDAQ: EBAY ) is going much higher. He explained that it's splitting up and bringing out value. Cloudera Inc (NYSE: CLDR ) missed ...